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Abstract
Cancer-cell survival, growth and metastatic potential are directed by dominant molecular signalling
patterns, the components of which have been shown to be qualitatively different from their normal
tissue counterparts. These signalling patterns can now be further distinguished by quantitative
assessment, either at a single point in time or at intervals. This commentary will focus on the
emergence of proteomic analysis which, in conjunction with the genomic expression data, is an
evolving technology that one day will enable personalized therapeutic strategies that are differentially
targeted against cancer.
Introduction and context
Alterations in the six essential functions defining the
neoplastic gene expression pattern collectively dictate
malignant growth. These functions include self suffi-
ciency, insensitivity to growth inhibition including
immune ‘escape’, circumvention of programmed cell
death, unlimited replicative potential, sustained angio-
genesis, and local and metastatic invasiveness [1].
Targeted therapeutics currently being used are directed
against derivatives of amplified genes and/or over-
expressed protein kinases in malignant cells involving
one or more of these core functions. Fifteen molecular
targeting therapies (Herceptin, Tykerb, Gleevec, Tasigna,
Rituxan, Bexxar, Avastin, Tarceva, Iressa, Vectibix,
Erbitux, Velcade, Sutent, Nexavar and Sprycel) have
already been approved by the US Food & Drug
Administration (FDA) for cancer treatment. Cancer
functions through a robust network with both adaptive
pliability and functional redundancy, which (with the
exception of chelates such as Bexxar) buffers the effect of
any single gene/target modification on the malignant
process [with some rare exceptions, such as chronic
myeloid leukaemia (CML)] [2]. For example, a number
of agents targeting epidermal growth factor receptor
(EGFR) have entered the clinic (Tarceva, Iressa, Vectibix,
and Erbitux) primarily for use in epithelial tumors. It
has recently been shown that EGFR inhibition will
induce upregulation of insulin-like growth factor 1
receptor (IGF-1R) resulting in a regulatory shift of Akt
from the EGFR pathway to the IGF pathway. A
reciprocal activation also occurs with IGF-1R inhibition
[3]. Mathematical analyses of targeting strategies (such
as antivirals and targeted therapies) of a variety of
biological systems suggest that a disruption of at least
three key biorelevant nodes will result in network
disarray. These data include modelling resistance in
CML [4], HIV viral escape following RNA interference
(RNAi) therapeutics [5], and the effectiveness of RNAi
at targeting Coxsackie virus [6]. A large number of
potential therapeutic targets exist and the list continues
to expand. Many are undergoing preclinical and clinical
testing with a variety of target specific agents (mono-
clonal antibodies, small molecules, antisense constructs,
ribozymes and RNAi technology) [7]. Unfortunately,
given the potential for targeted therapeutic development
and the availability of technology to assess genomic
networks relevant to cancer-cell function, there is a
discrepancy between the ability to identify presumptive
targets and their actual biological relevance and
integrated target sensitivity (the converse of robustness).
The necessity to more effectively interrogate and
quantify system functions, which would enable the
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sonalized therapeutics, has also become more glaring.
Based on our understanding of spatial distribution,
kinetics, and post-translational modifications, proteins
are thought to be the direct effectors of cellular behavior
rather than their DNA and intermediary mRNA tem-
plates. Characterization of protein expression provides
the most proximate assessment of cellular functional
activity. Proteins assemble themselves into complex
small-world networks composed of functional modules
with key regulatory hubs and interconnecting, informa-
tional, ‘bottleneck’ hubs[8],throughavarietyofprotein-
protein interactions. This protein-network based
approach has recently been used in the analysis of breast
cancer metastases [9]. We believe that characterization of
these interactions and in silico prediction of outcomes
from the reasoned and deliberate disruption of these
events will provide the basis for defining novel and more
effective target-complexes for drug therapy [10]. Gene
mutation, gene loss, and gene duplication or amplifica-
tion can result in absent, defective or overexpressed
proteins. These proteins realign within the cellular
protein network in a ‘degenerative’ pattern resulting in
an ‘oncopathologic’ hostile takeover [11]. Although
correlations of genomic patterns with survival have
been demonstrated in a variety of cancers, it remains
undetermined which of these anomalies are pathogenic
and which are not. Yet, we believe using new technol-
ogies, it is feasible to reduce the finite but unwieldy
number of overexpressed proteins in malignant tissue
into a manageable subset of candidate target-complexes
against which potentially effective multi-target therapies
can be constructed [12].
Major recent advances
Newer technology platforms, such as yeast two-hybrid
screens, forward-phase and reverse-phase protein arrays,
and protein chips, combined with emerging bioinfor-
matic analytic technologies, help define how proteins
interact with each other and will enable us to elucidate
and simulate functional modules within networks,
regulatory motifs and informational cross-talk linkages
[13].
The field of microarray technology has also rapidly
evolved. Over the last 5 years, it has become possible to
simultaneously analyze integrity and/or expression level
of hundreds of thousands of genes within days.
Microarray technology can be used to examine the
integrity of genome and gene expression levels; genomic
DNA analysis identifies the genes that have been
mutated, deleted or amplified, whereas RNA analysis
reveals differences in transcription and RNA processing.
Brown and Botstein [14] first reported the utilization of
microarray technology to examine gene expression
patterns in human malignancy in 1999. However, testing
of clinical samples in the past generally utilized admixed
tissue containing endothelial cells, stromal tissue, and
hematopoietic cells, in addition to cancer cells. As a
consequence, many of the reported gene expression
patterns of malignant cells are likely to be confounded
by these less than homogenous specimens. This poten-
tially confounding factor is now being addressed with
the routine implementation of laser capture microdissec-
tion (LCM). With this technique, malignant cells can be
s e l e c t i v e l yd i s s e c t e da n dc a p t u r e ds ot h a to n l ya
morphologically homogeneous population of cells is
investigated [15]. However, only a relatively small
amount of material is retrieved with the LCM process,
so the captured RNA requires amplification. As a result,
an unbalanced amplification of transcripts can lead to
misinterpretation of cancer gene expression levels.
Recent improvements in amplification technology are
addressing this concern.
Gene transcript levels often show poor correlation with
protein levels, and clearly cannot predict post-transcrip-
tional regulatory changes (for example, splicing) and
post-translational modifications (for example, phos-
phorylation, sulphation, and glycosylation) of the
encoded proteins. Proteomic technologies such as two-
dimensional difference gel electrophoresis (2D-DIGE),
bead capture, micro-enzyme-linked immunosorbent
assays (micro-ELISA), and liquid chromatography
aligned with tandem mass spectroscopy, are currently
employed for drug discovery and biomarker identifica-
tion [16]. Recent technologies quantifying mRNA and
protein signalling patterns have in fact been successfully
used to demonstrate that a finite number of genes are
unique to each individual cancer and that their
identification visualizes critical pathways or networks
which can be utilized for therapeutic targeting [17]. RNAi
technology is rapidly approaching clinical evaluation in
oncology. Early trials in primates indicate that its safety
and potency (as measured by knockdown of mRNA and
protein levels) is far greater than small molecules or
antisense constructs targeting the same gene products
[18].
Future directions
With these tools a mere step away from the bedside [19],
the challenge is now to identify a systems-dependent
target-complex as the network’s fragile site (its Achilles’
heel) so as to allow for the production of a therapy that
disarms the malignant ‘hostile takeover’. Therapeutic
targeting based on unique individual dynamic genomic/
proteomic constructs, differentially expressed, as opposed
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can now be envisioned. It is probable that future RNAi-
based gene therapy for cancer can be prescribed based on
the integrated mRNA proteomic expressionprofile ofeach
individual’s tumors. The accumulation of data from fresh
tissue obtained from the patient’st u m o r s( p r e f e r a b l y ,
primary and metastatic sites), the employment of LCM
with refined amplification technology, and the incorpora-
tion of quantitative genomic/proteomic methodologies
together with sophisticated modelling techniques provide
a means for automated construction of probabilistic
network models based on ‘real-world’ clinical data. This
will enable the rapid discovery and characterization of
tumor-specific oncogenic pathways that are responsive to
each individual patient’s needs within a realistic time
frame. Advances in genomic sequencing technology,
developed through the Human Genome Project, and
high throughput SNP (single nucleotide polymorphism)
analysis have resulted in the elucidation of consensus
coding sequences in a variety of human tumor types
[20,21] allowing for an increased depth of understanding
of intratumoral interactions such as synergy between
amplified and mutated genes in breast cancer [for
example, TGFb (transforming growth factor beta), Wnt
(wingless-type pathways), and FGF (fibroblast growth
factor)] [22].
Quantitative molecular profiling promises to change the
way oncology is practiced by enabling us to: (1) reformat
tumor classification using biomolecular parameters;
(2) individualize therapeutics; and (3) establish ‘early’
assessment of therapeutic efficacy using biorelevant
markers rather than volume-based endpoints. Further-
more, it will also enable a systems biological approach to
the understanding of the malignant process using
mathematical methods capable of virtualizing intracel-
lular signalling pathways, intercellular communications,
and cellular-environmental interactions.
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